Abeona Therapeutics Stock Price

0.21 (9.91%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Abeona Therapeutics Inc ABEO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.21 9.91% 2.33 16:24:01
Open Price Low Price High Price Close Price Prev Close
2.22 2.04 2.34 2.33 2.12
Bid Price Ask Price Spread News
2.31 2.32 0.01 1 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,234 6,142,300 $ 2.19 $ 13,434,939 2,496,913 0.9895 - 4.34
Last Trade Time Type Quantity Stock Price Currency
16:20:45 formt 400 $ 2.33 USD

Abeona Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 229.57M 98.53M 84.14M $ - $ - -1.52 -2.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Abeona Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ABEO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.952.381.902.063,749,9880.3819.49%
1 Month1.782.381.4651.852,280,3700.5530.9%
3 Months1.072.380.98951.582,282,1711.26117.76%
6 Months2.913.870.98951.551,957,244-0.58-19.93%
1 Year2.634.340.98952.041,620,410-0.30-11.41%
3 Years15.6022.000.98955.411,109,312-13.27-85.06%
5 Years2.8322.750.98956.60841,534-0.50-17.67%

Abeona Therapeutics Description

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-50X for the treatment of retinal diseases.

Your Recent History
Abeona The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.